\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Climate/Environment Green Deal“EASME" published the LIFE 2020 Call for Proposals from NGOs on the European Green Deal (NGO4GD).
The deadline for applying is Wednesday 31 March 2021 @ 17:00 (Brussels’ time).
A proposal must be submitted by a single non-profit making non-governmental organisation that is primarily active in the areas of environment and/or climate action and established in an EU member state.
There is a total indicative budget of 12 Mio EUR available. The maximum co-financing rate from LIFE 2020 NGO4GD is 60% of the total eligible project costs.
A virtual information session will be held on Tuesday 12 January 2021 from 10:00 to 12:45.
Organisations that meet the above mentioned eligibility criteria are invited to attend.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
